SKShekhar Kedia

Shekhar Kedia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shekhar Kedia has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Imaging nanoscopic co-assemblies of α-synuclein and Tau in human samples

    by Yu P. Zhang, Amber Wallis, Clara Obensa Bertroli, Cherida Zhang, Melanie Burke, Florence Layburn, Evgeniia Lobanova, Martin Furlepa, Shekhar Kedia, Yuhao Cui, et al.

    α-synuclein (αS), amyloid-β (Aβ), and Tau aggregates are hallmarks of many neurodegenerative diseases, yet the prevalence and nature of their nanoscopic co-assemblies remain poorly understood. Here, we adapt a single-molecule pull-down (SiMPull) assay to profile αS, Aβ, and Tau co-assemblies across post-mortem brain tissue homogenates, soluble brain fractions, human serum, cerebrospinal fluid, and saliva. We show that αS–Tau co-assemblies are abundant across all sample matrices, accounting for ~10–70% of total αS aggregates in both Parkinson’s disease (PD) and control samples. Notably, αS–Tau co-assemblies in soluble brain fractions from controls exhibit higher Proteinase K (PK) resistance than those from PD cases. Biophysically, Tau accelerates αS aggregation in simple in vitro systems, but this effect is suppressed in complex environments. Together, this work establishes a framework for probing co-assemblies, revealing that αS–Tau species possess heterogeneous biophysical features and are unlikely to act as a single, uniformly toxic species in PD pathology.


  • Open Access

    Downregulation of FBXO2 is associated with Aβ aggregation, tau hyperphosphorylation and network impairment in human cortical neurons

    by Michele Vendruscolo, Alicia Gonzalez Diaz, Andrea Possenti, Gustavo Urritia, Yuqi Bian, Shekhar Kedia, Dorothea Boeken, Christine Lim, Danilo Licastro, Benedetta Mannini, et al.

    Sporadic Alzheimer’s disease (sAD) arises from a complex interplay between genetic and environmental factors that remains poorly understood, making it challenging to develop accurate cell models that capture the molecular heterogeneity of the disease. In this study, we applied a systematic approach to identify potential transcriptomic promoters of sAD phenotypes by analysing single-nucleus RNA-seq data from the prefrontal cortex of early and late-stage AD patients. We experimentally tested 35 predicted genes using an Aβ aggregation assay in SH-SY5Y cells and functionally validated the shortlisted candidates in APPSwe and wild-type hiPSC-derived cortical neurons. Among the screened genes, FBXO2 knockdown increased measures consistent with amyloid aggregation in the cell models tested. In cortical neurons, FBXO2 knockdown was associated with increased Aβ oligomer secretion, elevated intracellular Aβ accumulation, tau hyperphosphorylation at disease-relevant sites (Ser396, Ser202/Thr205) and impaired electrophysiological function. Moreover, FBXO2 knockdown in wild-type neurons exposed to astrocyte-conditioned medium was accompanied by increased Aβ and tau phenotypes, while RNA sequencing revealed signatures of mitochondrial dysfunction. Together, these results illustrate a pipeline to prioritize candidate transcriptomic changes linked with AD-relevant states in human cortical neurons.

  • Open Access

    Cross-Species Aging Knowledge Integration into Agentic AI Platform Uncovers Conserved Mechanisms

    by Gaurav Ahuja, Arushi Sharma, Ankit Singh, Shekhar Kedia, Abhinav Sharma, Vishakha Gautam, Pranjal Sharma, Aniket Khandelwal, Sarayu Ramakrishna, Ravi Muddashetty, et al.

    Aging research has been advanced largely through the use of model organisms, where short lifespans and genetic tractability enable the systematic discovery of molecular pathways influencing longevity and age-related decline. However, knowledge about aging remains fragmented across species-specific repositories and domain-focused databases, limiting our ability to identify evolutionarily conserved mechanisms and translate findings to human biology. To address this gap, we developed EvoAge, a unified, multi-species knowledge graph that integrates aging-specific and general biomedical resources into a systems-level framework. EvoAge harmonizes 48 public datasets into a graph comprising 1.04 billion triples across six key species. A human-centric orthology framework reconciles more than 80,000 gene entries, expanding accessible organism-level aging knowledge by up to 1,700-fold compared with existing resources. To operationalize the graph for biological reasoning, we optimized knowledge graph embedding models and deployed a large language model (LLM)-assisted agentic interface that supports natural-language querying, link prediction, and hypothesis testing. In internal benchmarking using recent pre-print aging literature, EvoAge significantly outperformed state-of-the-art LLMs in distinguishing biologically plausible from implausible hypotheses. Importantly, EvoAge recommended a previously unrecognized Alzheimer’s disease (AD) mechanism involving nanoscale redistribution of BACE1 within synaptic compartments. We experimentally validated this EvoAge-supported prediction using patient-derived iPSCs carrying a familial PSEN1 mutation, demonstrating disease-associated remodeling of β-secretase, defined by altered localization, nanoscale clustering, and compartment-specific enrichment. We further confirmed the predicted evolutionary conservation of this BACE1–pathology relationship in additional AD systems, including transgenic mice and postmortem human brain tissue.

  • Open Access

    T-cell signaling relies on partial CD45-exclusion at sub-micron sized cellular contacts

    by Mateusz Kotowski, Daniel F. Heraghty, Markus Körbel, Debasis Banik, Ziwei Zhang, Shekhar Kedia, Bin Fu, James McColl, Bing Li, Joseph Clarke, et al.

    How cell contact initiates T-cell activation is uncertain. The local exclusion of the receptor-type protein tyrosine phosphatase CD45 at cell contacts is believed to trigger immune receptor signaling but this is yet to be observed for T cells interacting with authentic cellular targets. Here, quantitative imaging of T cells interacting with tumor cells presenting either native or clinically relevant bi-specific TCR ligands, revealed that they form multiple sub-micron sized ‘close contacts’ with their targets. The contacts were stabilised by the adhesion protein CD2, but efficient ligand detection required both CD2 and integrin ligation. CD45 was excluded from close contacts at the time of ZAP70 recruitment and signaling, but only partially (30− 40%). A single-cell, mass cytometric analysis showed that this change in kinase/phosphatase activity provoked strong T-cell activation and potent cytotoxicity via very small changes in signaling fluxes. Spatial stochastic simulations suggested that the proximal T-cell signaling network is optimised for efficient antigen discrimination in the setting of partial CD45 exclusion. Our work re-frames early T-cell activation as a process initiated by relatively subtle changes in kinase/phosphatase activity acting on small numbers of signaling effectors at minute cellular contacts.


  • Open Access

    The delayed kinetics of Myddosome formation explains why amyloid-beta aggregates trigger Toll-like receptor 4 less efficiently than lipopolysaccharide

    by Bing Li, Prasanna Suresh, Jack Brelstaff, Shekhar Kedia, Clare E Bryant, David Klenerman

    The Myddosome is a key innate immune signalling platform. It forms at the cell surface and contains MyD88 and IRAK proteins which ultimately coordinate the production of pro-inflammatory cytokines. Toll-like receptor 4 (TLR4) signals via the Myddosome when triggered by lipopolysaccharide (LPS) or amyloid-beta (Aβ) aggregates but the magnitude and time duration of the response are very different for reasons that are unclear. Here, we followed the formation of Myddosomes in live macrophages using local delivery of TLR4 agonist to the cell surface and visualisation with 3D rapid light sheet imaging. This was complemented by super-resolution imaging of Myddosomes in fixed macrophages to determine the size of the signalling complex at different times after triggering. Myddosomes formed more rapidly after LPS than in response to sonicated Aβ 1–42 fibrils (80 vs 372 s). The mean lifetimes of the Myddosomes were also shorter when triggered by LPS compared to sonicated Aβ fibrils (170 and 220 s), respectively. In both cases, a range of Myddosome of different sizes (50–500 nm) were formed. In particular, small round Myddosomes around 100 nm in size formed at early time points, then reduced in proportion over time. Collectively, our data suggest that compared to LPS the multivalency of Aβ fibrils leads to the formation of larger Myddosomes which form more slowly and, due to their size, take longer to disassemble. This explains why sonicated Aβ fibrils results in less efficient triggering of TLR4 signalling and may be a general property of protein aggregates.


  • Real-time heterogeneity of supramolecular assembly of amyloid precursor protein is modulated by an endocytic risk factor PICALM

    by Vivek Belapurkar, H S Mahadeva Swamy, Nivedita Singh, Shekhar Kedia, Subba Rao Gangi Setty, Mini Jose, Deepak Nair

    Recently, the localization of amyloid precursor protein (APP) into reversible nanoscale supramolecular assembly or “nanodomains” has been highlighted as crucial towards understanding the onset of the molecular pathology of Alzheimer’s disease (AD). Surface expression of APP is regulated by proteins interacting with it, controlling its retention and lateral trafficking on the synaptic membrane. Here, we evaluated the involvement of a key risk factor for AD, PICALM, as a critical regulator of nanoscale dynamics of APP. Although it was enriched in the postsynaptic density, PICALM was also localized to the presynaptic active zone and the endocytic zone. PICALM colocalized with APP and formed nanodomains with distinct morphological properties in different subsynaptic regions. Next, we evaluated if this localization to subsynaptic compartments was regulated by the C-terminal sequences of APP, namely, the “Y682ENPTY687” domain. Towards this, we found that deletion of C-terminal regions of APP with partial or complete deletion of Y682ENPTY687, namely, APP–Δ9 and APP–Δ14, affected the lateral diffusion and nanoscale segregation of APP. Lateral diffusion of APP mutant APP–Δ14 sequence mimicked that of a detrimental Swedish mutant of APP, namely, APP–SWE, while APP–Δ9 diffused similar to wild-type APP. Interestingly, elevated expression of PICALM differentially altered the lateral diffusion of the APP C-terminal deletion mutants. These observations confirm that the C-terminal sequence of APP regulates its lateral diffusion and the formation of reversible nanoscale domains. Thus, when combined with autosomal dominant mutations, it generates distinct molecular patterns leading to onset of Alzheimer’s disease (AD).


  • Does Altered Probability of Real Time Diffusional Collisions of Membrane Molecules Trigger or Delay Alzheimers Disease

    by Deepak Nair, Shekhar Kedia, Mini Jose

    Understanding stochastic events that control the molecular events leading to the onset of neurodegenerative diseases such as Alzheimer's Disease (AD) is not well understood. Though the bulk of the attention is attributed to the increased burden of detrimental proteoforms generated by the processing of Amyloid Precursor Protein, there lacks a clear consensus on how the molecular events that control the localization and trafficking contribute to the onset. Here, we discuss emerging evidence that indicate the role of nanoscale compositionality of the membrane and random diffusion at the millisecond time scale that contribute to the onset of AD. We believe that intuitive knowledge of nanobiology controlling the local rates of product formation holds the clue for next-generation therapeutics that might delay or halt the onset of AD.